FY2025 · ended Jun 30, 2025 · Revenue $4.94M, +7.5% YoY · Filed Sep 9, 2026
Inmed Pharmaceuticals Inc. (INM) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue (TTM)
$4.51M
-6.7% vs year-ago TTM
Net income (TTM)
$-1.20M
+84.8% vs year-ago TTM
Operating cash flow (TTM)
$-7.86M
+4.2% vs year-ago TTM
Free cash flow
$-7.00M
+6.0% vs prior year
EPS (TTM)
$-0.46
+96.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
5.49M
+130.4% vs prior year
Net cash
$10.05M
FY 2025
Operating margin
-192.2%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INM (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1728328
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | — | $4.9M | $4.6M | $4.1M | $1.1M |
| Operating income | — | — | — | -$7.9M | -$18.6M |
| Net income | -$12.6M | -$8.2M | -$7.7M | -$7.9M | -$18.6M |
| Diluted EPS | -$3.12 | -$8.36 | -$20.14 | -$3.25 | -$33.17 |
| Operating cash flow | -$8.6M | -$8.1M | -$7.0M | -$7.3M | -$15.6M |
| Free cash flow | — | — | -$7.0M | -$7.4M | -$15.6M |
| Total assets | $3.0M | $15.6M | $11.8M | $14.1M | $12.8M |
| Total liabilities | $2.0M | $2.1M | $2.6M | $2.0M | $3.7M |
| Stockholders' equity | $1.1M | $13.4M | $9.2M | $12.1M | $9.1M |
| Cash and investments | $2.2M | $10.8M | $6.6M | $9.0M | $6.2M |
| Total debt | — | $741,262 | $962,662 | $391,707 | $825,427 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Sep 18, 2026 | Sep 16, 2026 |
| 10-K | Annual report | Sep 9, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 22, 2026 | Jul 22, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 10, 2026 | Jul 6, 2026 |
All 512 Inmed Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.